GLP-1 receptor agonists × cardiovascular events

TrialEuropean heart journal2025

Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.

Kenneth W Mahaffey et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2025

Not counted

Probably reduced cardiovascular events

−18%−32% to −2%

Bigger than 4 in 10 for cardiovascular events

As reported

HR 0.82, 95% CI 0.68–0.98

One number in the abstract

the abstract, start to end

by 18% [hazard ratio (HR) 0.82 (95% confidence interval

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.820.68–0.98
GLP-1 receptor agonistsCardiovascular events
1 / 3

21 papers cite it

2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 39211948